Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Zura Bio Limited Class A Ordinary Shares (ZURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/12/2025: ZURA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.67
1 Year Target Price $13.67
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.87% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 64.97M USD | Price to earnings Ratio - | 1Y Target Price 13.67 |
Price to earnings Ratio - | 1Y Target Price 13.67 | ||
Volume (30-day avg) 7 | Beta -0.13 | 52 Weeks Range 0.97 - 5.07 | Updated Date 06/30/2025 |
52 Weeks Range 0.97 - 5.07 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.4% | Return on Equity (TTM) -55.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -104053378 | Price to Sales(TTM) - |
Enterprise Value -104053378 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.34 | Shares Outstanding 61875000 | Shares Floating 24675130 |
Shares Outstanding 61875000 | Shares Floating 24675130 | ||
Percent Insiders 29.16 | Percent Institutions 70.81 |
Analyst Ratings
Rating 3 | Target Price 13.67 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zura Bio Limited Class A Ordinary Shares
Company Overview
History and Background
Zura Bio Limited is a clinical-stage immunology company focused on developing novel medicines for inflammatory and autoimmune diseases. Founded in 2018, it aims to address unmet medical needs through targeted therapies.
Core Business Areas
- Therapeutic Development: Focuses on developing and commercializing innovative therapies for autoimmune and inflammatory diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Discovery: Engages in research activities to identify and develop new therapeutic targets.
Leadership and Structure
The company is led by a management team with experience in drug development and immunology. The organizational structure includes departments for research, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- Tibezonium Bromide (ZB-106): A potentially first-in-class anti-IL-17 monoclonal antibody for chronic inflammatory and autoimmune conditions. Currently in clinical development. Market share is not yet applicable. Competitors include Novartis (Cosentyx), Eli Lilly (Taltz), and UCB (Bimzelx).
Market Dynamics
Industry Overview
The autoimmune and inflammatory disease market is a large and growing market, driven by an aging population, increasing prevalence of chronic diseases, and advances in diagnostic and therapeutic options.
Positioning
Zura Bio is positioned as a clinical-stage company developing novel therapies for underserved patient populations within the autoimmune disease space, focusing on novel antibody and other therapeutic targets.
Total Addressable Market (TAM)
The global autoimmune disease market is estimated to be worth hundreds of billions of dollars. Zura Bio is focusing on a specific subset, anti-IL-17 therapies, which is a significant portion of the overall TAM.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Early stage clinical development
- Limited financial resources compared to larger competitors
- Reliance on successful clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in personalized medicine
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent disputes
Competitors and Market Share
Key Competitors
- NVS
- LLY
- UCB
Competitive Landscape
Zura Bio faces competition from established pharmaceutical companies with approved products in the autoimmune disease market. Zura Bio's success will depend on demonstrating superior efficacy and safety compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: N/A - Relatively new company
Future Projections: Future growth depends on successful clinical trial outcomes and commercialization of its drug candidates.
Recent Initiatives: Focusing on advancing ZB-106 through clinical trials.
Summary
Zura Bio is a clinical-stage company with innovative immunology treatments. Their success depends on clinical trials and potential partnerships. They are competing with larger established companies and need to manage cash well as they are not yet generating revenue. They face the risks of drug development which could prevent the success of the product.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zura Bio Limited Class A Ordinary Shares
Exchange NASDAQ | Headquaters Henderson, NV, United States | ||
IPO Launch date 2021-09-03 | CEO & Director Mr. Robert Lisicki | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://zurabio.com |
Full time employees 30 | Website https://zurabio.com | ||
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.